Diabetes and the risk of prostate cancer: the role of diabetes treatment and complications

Prostate Cancer Prostatic Dis. 2007;10(1):46-51. doi: 10.1038/sj.pcan.4500914. Epub 2006 Oct 10.

Abstract

Epidemiologic evidence suggests diabetic men have a slightly lower prostate cancer risk than non-diabetic men. We examined this association in a prospective cohort study of 35 239 men, 50-76 years old, in Washington State who completed a baseline questionnaire between 2000 and 2002. Incident prostate cancers as of 31 December 2004 were identified through the SEER registry. Diabetic men had a slightly lower risk of prostate cancer than non-diabetic men (hazard ratio (HR) 0.83, 95% confidence interval (CI) 0.64-1.07). Insulin users overall and insulin users with diabetic complications had decreased risks, compared to non-diabetic men (HR 0.49, 95% CI 0.26-0.92) and (HR 0.36, 95% CI 0.15-0.87), respectively. Oral medication use for diabetes was not associated with prostate cancer. Insulin is likely a marker of severity of diabetes. Future studies of this association should consider diabetes type, treatment, severity, complications and biomarkers.

MeSH terms

  • Administration, Oral
  • Aged
  • Carcinoma / epidemiology*
  • Carcinoma / etiology*
  • Cohort Studies
  • Diabetes Mellitus, Type 2 / complications*
  • Diabetes Mellitus, Type 2 / drug therapy
  • Diabetes Mellitus, Type 2 / epidemiology*
  • Humans
  • Hypoglycemic Agents / administration & dosage
  • Hypoglycemic Agents / adverse effects*
  • Insulin / administration & dosage
  • Male
  • Middle Aged
  • Prospective Studies
  • Prostatic Neoplasms / epidemiology*
  • Prostatic Neoplasms / etiology*
  • Risk Factors

Substances

  • Hypoglycemic Agents
  • Insulin